J&J Didn't Warn Of Risperdal Breast-Growth Risk, Jury Told

By Matt Fair (January 26, 2015, 5:43 PM EST) -- A treating physician told a Philadelphia jury on Monday that a Johnson & Johnson unit had not informed him about the risks associated with the antipsychotic drug Risperdal before he prescribed medication to a 7-year-old autistic boy who went on to grow female breasts.

Jan Mathisen, a clinical professor with the University of Alabama, testified on Monday that he would have re-evaluated his decision to prescribe the drug if the company had made him aware in 2002 that Risperdal could cause increased levels of the hormone prolactin resulting in abnormal growth of female breast tissue.

"With that potential risk, we would...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!